Winthrop Advisory Group LLC lifted its position in shares of Cigna Corp (NYSE:CI) by 62.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,608 shares of the health services provider’s stock after purchasing an additional 1,000 shares during the quarter. Winthrop Advisory Group LLC’s holdings in Cigna were worth $420,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV boosted its holdings in Cigna by 2,090.0% in the first quarter. Creative Financial Designs Inc. ADV now owns 657 shares of the health services provider’s stock worth $106,000 after acquiring an additional 627 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Cigna in the first quarter worth $1,169,000. New Potomac Partners LLC bought a new stake in Cigna in the first quarter worth $96,000. Brinker Capital Inc. boosted its holdings in Cigna by 44.6% in the first quarter. Brinker Capital Inc. now owns 47,635 shares of the health services provider’s stock worth $7,661,000 after acquiring an additional 14,689 shares in the last quarter. Finally, BB&T Corp boosted its holdings in Cigna by 7.0% in the first quarter. BB&T Corp now owns 14,764 shares of the health services provider’s stock worth $2,375,000 after acquiring an additional 961 shares in the last quarter. Institutional investors own 88.31% of the company’s stock.
In other Cigna news, Director John Partridge sold 1,000 shares of the business’s stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $184.43, for a total transaction of $184,430.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Michael W. Triplett sold 9,148 shares of the business’s stock in a transaction dated Monday, February 11th. The shares were sold at an average price of $181.01, for a total value of $1,655,879.48. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,420 shares of company stock valued at $1,886,122. 0.80% of the stock is owned by company insiders.
Cigna stock traded up $5.83 during mid-day trading on Tuesday, reaching $153.82. 4,211,761 shares of the stock traded hands, compared to its average volume of 2,959,663. The stock has a market cap of $56.63 billion, a PE ratio of 10.82, a price-to-earnings-growth ratio of 0.73 and a beta of 0.71. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.42 and a current ratio of 0.42. Cigna Corp has a 12-month low of $141.95 and a 12-month high of $226.60.
Cigna (NYSE:CI) last posted its quarterly earnings data on Friday, February 1st. The health services provider reported $2.46 EPS for the quarter, missing analysts’ consensus estimates of $2.53 by ($0.07). The firm had revenue of $13.75 billion for the quarter, compared to analysts’ expectations of $11.38 billion. Cigna had a net margin of 5.42% and a return on equity of 16.64%. The firm’s revenue was up 29.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.94 EPS. As a group, sell-side analysts predict that Cigna Corp will post 16.43 EPS for the current fiscal year.
The company also recently disclosed a special dividend, which was paid on Wednesday, April 10th. Investors of record on Monday, March 11th were given a dividend of $0.04 per share. The ex-dividend date was Friday, March 8th. Cigna’s dividend payout ratio (DPR) is presently 0.28%.
CI has been the subject of several recent analyst reports. Zacks Investment Research upgraded Cigna from a “hold” rating to a “strong-buy” rating and set a $171.00 price target for the company in a research note on Tuesday. UBS Group initiated coverage on Cigna in a research note on Tuesday. They issued a “buy” rating and a $185.00 price target for the company. Cantor Fitzgerald restated a “buy” rating and issued a $245.00 price target on shares of Cigna in a research note on Sunday. ValuEngine cut Cigna from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 18th. Finally, Barclays decreased their price target on Cigna from $220.00 to $207.00 and set an “overweight” rating for the company in a research note on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $225.62.
COPYRIGHT VIOLATION WARNING: “Winthrop Advisory Group LLC Grows Position in Cigna Corp (CI)” was published by Macon Daily and is owned by of Macon Daily. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://macondaily.com/2019/04/23/winthrop-advisory-group-llc-grows-position-in-cigna-corp-ci.html.
Cigna Corporation, a health service organization, provides insurance and related products and services in the United States and internationally. It operates through Integrated Medical, Health Services, International Markets, and Group Disability and Other segments. The Integrated Medical segment offers medical, pharmacy, dental, behavioral health and vision, health advocacy programs, and other products and services to insured and self-insured clients; Medicare Advantage, Medicare Supplement, and Medicare Part D plans to Medicare-eligible beneficiaries, as well as Medicaid plans; and health insurance coverage to individual customers on and off the public exchanges.
Read More: What is the NASDAQ?
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.